LIGAND PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| LIGAND PHARMACEUTICALS INCORPORATED | |
|---|---|
| By: | /S/ TODD C. DAVIS |
| Todd C. Davis, | |
| Chief Executive Officer | |
Date: February 27, 2026
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ TODD C. DAVIS | Chief Executive Officer and Director (Principal Executive Officer) | February 27, 2026 |
| Todd C. Davis | ||
| /s/ OCTAVIO ESPINOZA | Chief Financial Officer (Principal Financial and Accounting Officer) | February 27, 2026 |
| Octavio Espinoza | ||
| /s/ JOHN W. KOZARICH | Director and Chairman of the Board | February 27, 2026 |
| John W. Kozarich | ||
| /s/ JASON M. ARYEH | Director | February 27, 2026 |
| Jason M. Aryeh | ||
| /s/ NANCY R. GRAY | Director | February 27, 2026 |
| Nancy R. Gray | ||
| /s/ JASON HAAS | Director | February 27, 2026 |
| Jason Haas | ||
| /s/ JOHN L. LAMATTINA | Director | February 27, 2026 |
| John L. LaMattina | ||
| /s/ STEPHEN L. SABBA | Director | February 27, 2026 |
| Stephen L. Sabba | ||
| /s/ MARTINE ZIMMERMANN | Director | February 27, 2026 |
| Martine Zimmermann | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.